BackVasamed Overview

Vasamed EBIT

Vasamed's EBIT is $-4.6M, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$1.24M
↑ 22.08% YoY

As of Sep 30, 2006

Annual EBIT (TTM)

-$4.63M
↑ 0.79% YoY

Trailing 12 months ending Sep 30, 2006

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Vasamed (VSMD) FAQ

The latest EBIT for VSMD is $-4.6M as of September 2006. That compares with $-4.7M in the prior-year period — up 0.8% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Vasamed's historical trend and sector peers before judging valuation or financial health.

Over the past year, VSMD's EBIT moved from $-4.7M to $-4.6M — a 0.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vasamed's operating scale or balance-sheet position.

Against its sector companies, VSMD currently prints $-4.6M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Vasamed's growth, margins, and balance sheet.

A EBIT figure of $-4.6M for VSMD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting VSMD's EBIT ($-4.6M), review year-over-year change from $-4.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.